(19)
(11) EP 2 936 157 A1

(12)

(43) Date of publication:
28.10.2015 Bulletin 2015/44

(21) Application number: 13815744.1

(22) Date of filing: 20.12.2013
(51) International Patent Classification (IPC): 
G01N 33/574(2006.01)
C07K 14/74(2006.01)
 A61K 47/48(2006.01)
(86) International application number:
PCT/EP2013/077702
(87) International publication number:
WO 2014/096367 (26.06.2014 Gazette 2014/26)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 21.12.2012 EP 12382522

(71) Applicants:
  • Servicio Andaluz de Salud
    41071 Sevilla (ES)
  • Fundacion publica andaluza para la investigacion biosanitaria de andalucia oriental - Alejandro Otero
    18012 Granada (ES)
  • Universidad De Granada
    18071 Granada (ES)

(72) Inventors:
  • GARRIDO TORRES-PUCHOL, Federico
    18012 Granada (ES)
  • DEL CAMPO ALONSO, Ana Belén
    18012 Granada (ES)
  • APTSIAURI, Natalia
    18012 Granada (ES)
  • CARRETERO COCA, Rafael
    18012 Granada (ES)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)

   


(54) EXPRESSION OF BETA2-MICROGLOBULIN AS A PROGNOSTIC MARKER FOR TUMOUR IMMUNE ESCAPE AND RESISTANCE TO CANCER IMMUNOTHERAPY AND A DIAGNOSTIC BIOMARKER FOR PATIENT SELECTION FOR SPECIFIC GENE THERAPY